Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 54 entries
View as:

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04803994 Org: User:
Start: 07/06/21 End: 07/31/27 Due: 07/31/28

Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06731803 Org: User:
Start: 03/25/25 End: 12/31/27 Due: 12/31/28

Fedratinib in Combination with Nivolumab

Phase: N/A Priority: Normal
NCT ID: NCT05393674 Org: User:
Start: 06/14/22 End: 06/30/26 Due: 06/30/27

Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT06050434 Org: User:
Start: 10/31/23 End: 07/30/24 Due: 07/30/25

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03252938 Org: User:
Start: 08/15/17 End: 09/30/25 Due: 09/30/26

Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness

Phase: N/A Priority: Normal
NCT ID: NCT03421288 Org: User:
Start: 09/14/18 End: 12/31/27 Due: 12/31/28

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06207734 Org: User:
Start: 01/17/24 End: 07/10/28 Due: 07/10/29

Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

Phase: N/A Priority: Normal
NCT ID: NCT06981325 Org: User:
Start: 06/30/25 End: 07/31/29 Due: 07/31/30

Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04351256 Org: User:
Start: 05/20/20 End: 06/30/26 Due: 06/30/27

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Phase: N/A Priority: Normal
NCT ID: NCT05174650 Org: User:
Start: 04/20/22 End: 08/31/26 Due: 08/31/27

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05239169 Org: User:
Start: 05/23/22 End: 02/20/25 Due: 02/20/26

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Phase: N/A Priority: Normal
NCT ID: NCT04522544 Org: User:
Start: 12/15/20 End: 12/31/26 Due: 12/31/27

GISAR German Interdisciplinary Sarcoma Registry

Phase: N/A Priority: Normal
NCT ID: NCT04122872 Org: User:
Start: 11/29/18 End: 01/31/38 Due: 01/31/39

Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05504720 Org: User:
Start: 02/13/23 End: 12/31/27 Due: 12/31/28

Comprehensive Genomic Profiling Combined With Real Life Data of "The German-Registry of Incidental Gallbladder Carcinoma"

Phase: N/A Priority: Normal
NCT ID: NCT05222854 Org: User:
Start: 10/11/17 End: 12/31/99 Due: 12/31/00

Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements

Phase: N/A Priority: Normal
NCT ID: NCT05565794 Org: User:
Start: 11/11/22 End: 03/27/25 Due: 03/27/26

Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03530267 Org: User:
Start: 09/28/18 End: 02/01/24 Due: 02/01/25

RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT03520946 Org: User:
Start: 01/24/19 End: 07/30/24 Due: 07/30/25

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03647969 Org: User:
Start: 11/07/18 End: 07/19/24 Due: 07/19/25

IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)

Phase: N/A Priority: Normal
NCT ID: NCT03753659 Org: User:
Start: 05/09/19 End: 04/30/24 Due: 04/30/25

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Phase: N/A Priority: Normal
NCT ID: NCT05825625 Org: User:
Start: 05/26/23 End: 06/01/27 Due: 06/01/28

Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

Phase: N/A Priority: Normal
NCT ID: NCT04511455 Org: User:
Start: 12/08/20 End: 12/31/24 Due: 12/31/25

The PLATON Network

Phase: N/A Priority: Normal
NCT ID: NCT05489250 Org: User:
Start: 10/28/20 End: 05/31/32 Due: 05/31/33

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Phase: N/A Priority: Normal
NCT ID: NCT05798156 Org: User:
Start: 03/20/23 End: 09/30/28 Due: 09/30/29

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Phase: N/A Priority: Normal
NCT ID: NCT04238637 Org: User:
Start: 11/01/19 End: 12/31/25 Due: 12/31/26